NCT02406508: Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC |
|
|
| Withdrawn | 2 | 0 | US | Melphalan/HDS, Melphalan/Hepatic Delivery System, Percutaneous hepatic perfusion (PHP), Sorafenib, Nexavar | Delcath Systems Inc. | Hepatocellular Carcinoma (HCC) | 12/17 | 12/17 | | |
NCT02415036 / 2014-001585-98: Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma |
|
|
| Terminated | 2 | 17 | Europe | Delcath Hepatic Delivery System, Melphalan/Hepatic Delivery System, Percutaneous hepatic perfusion (PHP), Melphalan | Delcath Systems Inc. | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 10/18 | 12/18 | | |
NCT06607458: Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Colorectal Cancer W/liver Dominant Disease |
|
|
| Not yet recruiting | 2 | 90 | NA | Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil, Melphalan/HDS, Trifluridine-tipiracil plus Bevacizumab Alone, Bevacizumab | Delcath Systems Inc. | Refractory Metastatic Colorectal Cancer | 12/26 | 10/27 | | |
